Cargando…

Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12

Detalles Bibliográficos
Autores principales:	Walter, H S, Jayne, S, Mensah, P, Miall, F M, Lyttelton, M, Dyer, M J S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5141357/ https://www.ncbi.nlm.nih.gov/pubmed/27315112 http://dx.doi.org/10.1038/bcj.2016.42

Ejemplares similares

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
por: Seiter, Karen, et al.
Publicado: (2015)

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
por: Luan, Chunyan, et al.
Publicado: (2019)

BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib
por: Jackson, Ross A., et al.
Publicado: (2023)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
por: Saba, Julie, et al.
Publicado: (2017)

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab
por: Shah, Arpita
Publicado: (2015)

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
por: Smolej, Lukáš
Publicado: (2014)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
por: Al-Sawaf, Othman, et al.
Publicado: (2017)

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
por: Khurana, Sharad, et al.
Publicado: (2019)

Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia
por: Maura, Francesco, et al.
Publicado: (2015)

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
por: Hill, Brian T, et al.
Publicado: (2015)

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
por: Cerquozzi, Sonia, et al.
Publicado: (2015)

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus
por: Freund, Johanna, et al.
Publicado: (2022)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Written in Blood: Kissing Disease miRNAs Could Predict Outcome of Patients With Chronic Lymphocytic Leukaemia
por: Lawrie, Charles H.
Publicado: (2015)

Hemostatic resuscitation for acute traumatic coagulopathy
por: Scalea, Thomas M
Publicado: (2011)

Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?
por: Langerak, Anton W., et al.
Publicado: (2020)

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021)

Posterior Reversible Encephalopathy Syndrome Triggered by Obinutuzumab in a Patient with Chronic Lymphocytic Leukemia
por: Atef, Bentolhoda, et al.
Publicado: (2023)

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review
por: Autore, Francesco, et al.
Publicado: (2018)

Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways
por: Abruzzo, Lynne V., et al.
Publicado: (2018)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21
por: Ganghammer, Sylvia, et al.
Publicado: (2015)

Fluid-induced coagulopathy: does the type of fluid make a difference?
por: Marx, Gernot, et al.
Publicado: (2010)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib
por: Haddad, Fady Gh, et al.
Publicado: (2021)

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
por: Sharman, Jeff P., et al.
Publicado: (2022)

Fibrinogen depletion in trauma: early, easy to estimate and central to trauma-induced coagulopathy
por: Davenport, Ross, et al.
Publicado: (2013)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Is fibrinogen the answer to coagulopathy after massive transfusions?
por: Tisherman, Samuel A
Publicado: (2010)

Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
por: Elbeddini, Ali, et al.
Publicado: (2020)

P1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
por: Kanevsky, D., et al.
Publicado: (2022)

Transformation of cytogenetically normal chronic myelomonocytic leukaemia to an acute myeloid leukaemia and the emergence of a novel +13,+15 double trisomy resulting in an adverse outcome
por: McGrattan, Peter, et al.
Publicado: (2007)

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
por: Holmes, Katie B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pfvrlnge4vm69hc87kmj0c9cnl